Docosahexaenoic acid (DHA) in stroke, Alzheimer’s disease, and blinding retinal degenerations: coping with neuroinflammation and sustaining cell survival

Bazán, Nicolás G.; Asatryan, Aram

doi:10.1051/ocl.2011.0403

Cited by 3 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After controlling for various signaling and synaptic homeostasis when disruptions and neurodegenerative mechanisms occur [28]. NPD1 inhibits amyloidogenic processing of APP and attenuates pro-inflammatory gene expressions including TNF-a and cyclooxygenase-2 [29]. DHA and DHA-derived lipid mediators exert antioxidant, anti-inflammatory and antiapoptic actions.…”

Section: Epa Dha and Npd1 In Admentioning

confidence: 99%

Dietary Neurolipidomics in Alzheimer's Disease

Efstathia¹,

Vlamos²

2022

J Nutri Med Diet Care

View full text Add to dashboard Cite

The promising area of lipidomics has received a major interest as exploring panels of lipid biomarkers and their metabolic pathways might contribute to the early diagnosis of Alzheimer's disease allowing novel therapeutic targets. Dysfunctions in lipid metabolism have been associated with metabolic disorders as well as with aging and neurodegenerative diseases. Neurolipidomics is beginning to provide new insights into the pathophysiology of AD through identification of plasma and cerebral lipid mediators and metabolites (lipidome). Altered lipid profile and dysregulated metabolism of DHA, plasmalogen, phosphoinositol (PI), phosphoethanolamine (PE) has been investigated mainly through their incorporation into neuronal membranes and may all contribute to AD progression. This review summarizes the current knowledge on altered lipidome in AD and the impact of dietary lipids (cholesterol, phospholipids, SF, LA, AA, EPA, DHA) on the brain, CSF and plasma lipidome in MCI and AD subjects compared to age-matched controls.

show abstract

Section: Epa Dha and Npd1 In Admentioning

confidence: 99%